Ecuador Ley Organica de Salud: Legal Basis for Medical Device Regulation

1. Key takeaways

The source of all medical device regulatory power in Ecuador is the Ley Organica de Salud (Organic Health Law, Ley 67/2006). Its Article 132 authorizes health surveillance and control, Article 134 governs permits for commercial establishments, and Article 138 constitutes the superior legal basis for procedure fees. Article 72 of the new regulation traces sanctions for violations directly back to this law, and expressly states that it does not affect the pursuit of civil, administrative and criminal liability.

2. Legal basis

Verification note: the subject matter of Articles 132, 134 and 138 is taken from the text indexed in the ILO NATLEX database; the fee-related character of Article 138 is corroborated in reverse by the preamble of the new regulation, whose Visto section cites the ministerial accord under its full name as the fee schedule for procedures executed under Article 138 of the Ley Organica de Salud.

3. Expert insights

Insight one: Article 138 makes fees a statutory matter rather than a matter of negotiation. Article 8 of the new regulation only provides that registration, renewal and changes are subject to the fees (tasas) currently in force at ARCSA, without stating any amount; the amounts sit in the ministerial accord issued under Article 138 and in subsequent ARCSA fee resolutions. This structure, in which the regulation sets the principle and the fees are published separately, means that official fees can be adjusted without amending the registration regulation itself, so multi-year budgets should retain flexibility.

Insight two: the operating permit under Article 134 is the legal origin of the establishment obligation. It does not target products; it targets the establishments engaged in manufacturing, import, distribution, storage and commercialization. Article 60 of the new regulation builds on it by requiring establishments to hold a valid operating permit and to carry out only the activities stated in the permit document. This is the first threshold for judging whether a license holder or channel partner is qualified.

Insight three: Article 72 connects the technical regulation to the parent law, and the liability is triple. The new regulation contains no sanction articles of its own; Article 72 provides that violations are punished under the Ley Organica de Salud and other laws in force, without prejudice to any civil, administrative and criminal liability that may arise. This means that conduct such as concealing adverse events carries, beyond administrative sanctions, a real exposure to civil damages and criminal prosecution.

Insight four: the operating permit and the health registration are two independent obligations that share the same legal authorization. A product without registration and an establishment without a permit breach different obligations, yet the basis for sanctions is the same. A single enforcement inspection can trigger liability on both lines at once.

Insight five: across the full text of the new regulation the name ARCSA appears 178 times, while the names Alberto Cornejo and ARCSA-AC appear 0 times. The full name of the signing body is Agencia Nacional de Regulacion, Control y Vigilancia Sanitaria – ARCSA, Doctor Leopoldo Izquieta Perez. When verifying the authenticity of official documents, the full institutional name is a reliable anchor.

4. Practical recommendations

1. Check the operating permit before signing with a license holder: verify that the permitted activity categories include import and distribution and that the validity period covers the submission cycle.
2. Assess channel partners under Article 134 rather than on commercial credit: a suspended permit will directly stop goods from circulating.
3. Verify the fee budget on two layers, the regulation plus the current tasas, and never carry forward historical amounts.
4. Write the triple liability of Article 72 into agreements with license holders, allocating responsibility for concealed or late adverse event reporting.
5. Maintain a sanctions risk ledger and run periodic self-checks on the high-frequency violation points of labeling, vigilance and traceability.

5. Verification checklist

• □ Official or authoritative database texts of Articles 132, 134 and 138 of the Ley Organica de Salud have been obtained
• □ The activity categories and validity period of the license holder operating permit have been checked
• □ Official fees have been recalculated against the current ARCSA tasas, without carrying forward historical amounts
• □ The agreement with the license holder allocates responsibility for violations
• □ The technical director has been confirmed to hold the statutory qualifications required by Article 60
• □ The full institutional name on every cited ARCSA document has been verified as complete

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation